Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Professor Harry Crijns

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

9 More presentations in this session

Presentation thumbnail

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Doctor G. Montrasio (Aarau, CH)

Abstract Slides

Presentation thumbnail

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Doctor W. Amara (Le Raincy-Montfermeil, FR)

Presentation thumbnail

Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Doctor M. Mihajlovic (Belgrade, RS)

Abstract Slides

Presentation thumbnail

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Associate Professor M. Harada (Toyoake, JP)

Presentation thumbnail

Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Doctor O. Hajas (Debrecen, HU)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 2 - Drug treatment for atrial fibrillation

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

Interactive discussion and Q&A

Congress Session

Treatment strategies for atrial fibrillation in heart failure

Congress Session

EHRA Myths - Device-detected atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources